Unlocking the potential of TRPV1 based siRNA therapeutics for the treatment of chemotherapy-induced neuropathic pain

Akhilesh, .; Uniyal, Ankit; Gadepalli, Anagha; Tiwari, Vineeta; Allani, Meghana; Chouhan, Deepak; Ummadisetty, Obulapathi; Verma, Nimisha

doi:10.1016/j.lfs.2021.120187

Cited by 31 publications

(15 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Brain Inflammationmentioning

confidence: 99%

“…Yet, current treatment opportunities for the hemorrhage involved no particular involvement in the therapeutic preferences (Kandil et al, 2020). Similarly, glioblastoma (GBM) is also related to aggression in chronic inflammation, where IL‐6 cytokines are highly associated with GBM (Akhilesh et al, 2022). One of the novel treatment strategies is gaining huge interest due to the successful target binding and crossing of biological brain barriers (Del prado‐Audelo et al, 2019; Zhang et al, 2021).…”

Section: Imdsmentioning

confidence: 99%

See 1 more Smart Citation

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

Sargazi

Arshad

Ghamari

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

Immune-mediated diseases (IMDs) are chronic conditions that have an immunemediated etiology. Clinically, these diseases appear to be unrelated, but pathogenic pathways have been shown to connect them. While inflammation is a common occurrence in the body, it may either stimulate a favorable immune response to protect against harmful signals or cause illness by damaging cells and tissues. Nanomedicine has tremendous promise for regulating inflammation and treating IMIDs. Various nanoparticles coated with nanotherapeutics have been recently fabricated for effective targeted delivery to inflammatory tissues. RNA interference (RNAi) offers a tremendous genetic approach, particularly if traditional treatments are ineffective against IMDs. In cells, several signaling pathways can be suppressed by using RNAi, which blocks the expression of particular messenger RNAs. Using this molecular approach, the undesirable effects of anti-inflammatory medications can be reduced. Still, there are many problems with using short-interfering RNAs (siRNAs) to treat IMDs, including poor localization of the siRNAs in target tissues, unstable gene expression, and quick removal from the blood. Nanotherapeutics have been widely used in designing siRNA-based carriers because of the restricted therapy options for IMIDs. In this review, we have discussed recent trends in the fabrication of siRNA nanodelivery systems, including lipid-based siRNA nanocarriers, liposomes, and cationic lipids, stable nucleic acid-lipid particles, polymeric-based siRNA nanocarriers, polyethylenimine (PEI)-based nanosystems, chitosan-based nanoformulations, inorganic material-based siRNA nanocarriers, and hybrid-based delivery systems. We have also introduced novel siRNA-based nanocarriers to

show abstract

Section: Brain Inflammationmentioning

confidence: 99%

Section: Imdsmentioning

confidence: 99%

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

Sargazi

Arshad

Ghamari

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…The transformation to electrical signals proceeds through activation of receptors or ion channels that detect different kinds of stimuli ( 15 ). The transient receptor potentials (or TRP, TRPV1-4, TRPM8, TRPA1) ( 18 )—especially the transient receptor potential vanilloid 1 channel (TRPV1)—are known to be especially important in mammals due to their function as molecular integrators and regulators of harmful stimuli and their participation in developing nocifensive behaviors and physiological responses to pain ( 21 , 22 ).…”

Section: Recent Findings In the Study Of The Neurobiology Of Pain In ...mentioning

confidence: 99%

The neurobiology of pain and facial movements in rodents: Clinical applications and current research

et al. 2022

View full text Add to dashboard Cite

One of the most controversial aspects of the use of animals in science is the production of pain. Pain is a central ethical concern. The activation of neural pathways involved in the pain response has physiological, endocrine, and behavioral consequences, that can affect both the health and welfare of the animals, as well as the validity of research. The strategy to prevent these consequences requires understanding of the nociception process, pain itself, and how assessment can be performed using validated, non-invasive methods. The study of facial expressions related to pain has undergone considerable study with the finding that certain movements of the facial muscles (called facial action units) are associated with the presence and intensity of pain. This review, focused on rodents, discusses the neurobiology of facial expressions, clinical applications, and current research designed to better understand pain and the nociceptive pathway as a strategy for implementing refinement in biomedical research.

show abstract

“…In addition, red ginseng extract has an inhibitory effect on histamine-induced itch sensation by inhibition of the H1R/TRPV1 ion channel present in DRG neurons ( Jang et al, 2015 ). Noteworthy, TRPV1 is a non-selective cation channel highly expressed in DRG neurons and the spinal cord, believed to serve as a viable target in the regulation of chemotherapy-induced neuropathic pain ( Akhilesh et al, 2022 ). Rg1 blocks intracellular calcium by both capsaicin and proton activation in a TRPV1-dependent manner indicating its potential as an antagonist of TRPV1 ( Huang et al, 2012 ).…”

Section: Mechanism Of Action Target and Signaling Pathwaysmentioning

confidence: 99%

Progress on the Elucidation of the Antinociceptive Effect of Ginseng and Ginsenosides in Chronic Pain

Wei

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Ginseng (Panax ginseng C.A. Meyer) is a traditional Oriental herbal drug widely used in East Asia. Its main active ingredients are ginsenosides whose constituents are known to have various pharmacological activities such as anticancer, antinociception, and neuroprotection. The analgesic effects of ginsenosides, such as Rg1, Rg2, and Rb1, as well as compound K, are well known and the analgesic mechanism of action in inflammatory pain models is thought to be the down regulation of pro-inflammatory cytokine expression (TNF-α IL-1β, and IL-6). Several studies have also demonstrated that ginsenosides regulate neuropathic pain through the modulation of estrogen receptors. Recently, an increasing number of pathways have emerged in relation to the antinociceptive effect of ginseng and ginsenosides. Therefore, this review presents our current understanding of the effectiveness of ginseng in chronic pain and how its active constituents regulate nociceptive responses and their mechanisms of action.

show abstract

Unlocking the potential of TRPV1 based siRNA therapeutics for the treatment of chemotherapy-induced neuropathic pain

Cited by 31 publications

References 150 publications

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

The neurobiology of pain and facial movements in rodents: Clinical applications and current research

Progress on the Elucidation of the Antinociceptive Effect of Ginseng and Ginsenosides in Chronic Pain

Contact Info

Product

Resources

About